Value-based healthcare: implications for thyroid cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Porter ME, Teisberg ED. Redefining Healthcare: Creating Value-Based Competition on Results. Harvard Business School Press, Boston, MA, USA (2006). •• The definitive textbook that began the value-based healthcare movement in the USA.
  Google Scholar
• 2 Porter ME, Lee TH. The strategy that will fix healthcare. Hav. Bus. Rev. 91(10), 50–70 (2013). • A concise review of the six essential aspects of creating a value-based healthcare program.
  MedlineGoogle Scholar
• 3 Porter ME. What is value in healthcare? N. Engl. J. Med. 363(26), 2477–2481 (2010).
  Medline CASGoogle Scholar
• 4 Kaplan RS, Porter ME. How to solve the cost crisis in healthcare. Hav. Bus. Rev. 89(9), 47–64 (2011). •• Reviews a new approach to controlling spiraling healthcare costs – accurate measurement.
  Google Scholar
• 5 French KE, Albright HW, Frenzel JC et al. Measuring the value of process improvement initiatives in a preoperative assessment center using time-driven activity-based costing. Healthcare 1(3–4), 136–142 (2013). • Describes how accurate costing can be used to shape and assess performance improvement.
  Google Scholar
• 6 Porter ME, Clifford MM, Landman ZC. Orthochoice: bundled payments in the county of Stockholm (a). Harvard Business School Supplement. (Case 714–514), (2015).
  Google Scholar
• 7 SEER stat fact sheets: Thyroid cancer (2015). www.seer.cancer.gov/statfacts/html/thyro.html.
  Google Scholar
• 8 Sherman SI. Thyroid carcinoma. Lancet 361(9356), 501–511 (2003).
  MedlineGoogle Scholar
• 9 Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head Neck Surg. 140(4), 317–322 (2014).
  MedlineGoogle Scholar
• 10 Aschebrook-Kilfoy B, Schechter RB, Shih YC et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epideomiol Biomakers Prev. 22(7), 1252–1259 (2013).
  MedlineGoogle Scholar
• 11 Ramsey S, Blough D, Kirchhoff A et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health affairs. 32(6), 1143–1152 (2013).
  MedlineGoogle Scholar
• 12 Haugen BR, Alexander EK, Bible KC et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2015). • The most updated US guidelines on the management of differentiated thyroid cancer.
  Google Scholar
• 13 Tuttle RM, Haddad RI, Ball DW et al. Thyroid carcinoma, version 2.2014. J. Natl Compr. Canc. Netw. 12(12), 1671–1680; quiz 1680 (2014).
  MedlineGoogle Scholar
• 14 Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009).
  MedlineGoogle Scholar
• 15 Roman BR, Feingold JH, Patel SG et al. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm. Thyroid 24(10), 1549–1550 (2014).
  MedlineGoogle Scholar
• 16 AJCC Cancer Staging Manual (7th Edition). Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). Springer, NY, USA (2010).
  Google Scholar
• 17 Francis G, Waguespack SG, Bauer AJ et al. American Thyroid Association Guidelines Task Force. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 25(7), 716–759 (2015). • First published US guidelines on the management of differentiated thyroid cancer in the pediatric population.
  MedlineGoogle Scholar
• 18 Rivkees SA, Mazzaferri EL, Verburg FA et al. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev. 32(6), 798–826 (2011).
  Medline CASGoogle Scholar
• 19 Aschebrook-Kilfoy B, Ward MH, Sabra MM et al. Thyroid cancer incidence patterns in the United States by histologic type,1992–2006. Thyroid 21(2), 125–134 (2011).
  MedlineGoogle Scholar
• 20 Wells SA Jr, Asa SL, Dralle H et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6), 567–610 (2015). • The most updated US guidelines on the management of medullary thyroid cancer.
  MedlineGoogle Scholar
• 21 Vigersky RA, Fish L, Hogan P et al. The clinical endocrinology workforce: Current status and future projections of supply and demand. J. Clin. Endocrinol. Metab. 99(9), 3112–3121 (2014).
  Medline CASGoogle Scholar
• 22 Schneider DF, Ojomo KA, Chen H et al. Remnant uptake as a postoperative oncologic quality indicator. Thyroid 23(10), 1269–1276 (2013).
  MedlineGoogle Scholar
• 23 Loyo M, Tufano RP, Gourin CG. National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope 123(8), 2056–2063 (2013).
  MedlineGoogle Scholar
• 24 Stavrakis AI, Ituarte PH, Ko CY et al. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery 142(6), 887–899 (2007).
  MedlineGoogle Scholar
• 25 Youngwirth LM, Adam MA, Scheri RP et al. Patients treated at low-volume centers have higher rates of incomplete resection and compromised outcomes: analysis of 31,129 patients with papillary thyroid cancer. Ann. Surg. Onco. 23(2), 403–409 (2015).
  MedlineGoogle Scholar
• 26 Haymart MR, Banerjee M, Yang D et al. Variation in the management of thyroid cancer. J. Clin. Endocrinol. Metab. 98(5), 2001–2008 (2013).
  Medline CASGoogle Scholar
• 27 Haymart MR, Banerjee M, Yang D et al. The relationship between extent of thyroid cancer surgery and use of radioactive iodine. Ann. Surg. Oncol. 258(2), 354–358 (2013).
  Google Scholar
• 28 Schuessler KM, Banerjee M, Yang D et al. Surgeon training and use of radioactive iodine in stage i thyroid cancer patients. Ann. Surg. Oncol. 20(3), 733–738 (2013).
  MedlineGoogle Scholar
• 29 Haymart MR, Banerjee M, Yang D et al. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. Cancer 119(2), 259–265 (2013).
  Medline CASGoogle Scholar
• 30 Wang TS, Roman SA, Sosa JA. Predictors of outcomes following pediatric thyroid and parathyroid surgery. Curr. Opin Oncol. 21(1), 23–28 (2009).
  MedlineGoogle Scholar
• 31 Sacks W, Wong RM, Bresee C et al. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer. Thyroid 25(4), 377–385 (2015).
  Medline CASGoogle Scholar
• 32 Gning I, Trask PC, Mendoza TR et al. Development and initial validation of the thyroid cancer module of the M.D. Anderson symptom inventory. Oncology 76(1), 59–68 (2009).
  MedlineGoogle Scholar
• 33 Dadu R, Hu MI, Cleeland CS et al. The efficacy of the natural clay, casad, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: a pilot study. Thyroid 24(S1), P166 (2014).
  Google Scholar
• 34 Steele JR, Clarke RK, Terrell JA et al. Improving patient access to an interventional us clinic. Radiographics 34(1), e18–e23 (2014).
  MedlineGoogle Scholar
• 35 Tuttle RM, Tala H, Shah J et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new american thyroid association staging system. Thyroid 20(12), 1341–1349 (2010).
  Medline CASGoogle Scholar
• 36 Lindsey SC, Ganly I, Palmer F et al. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 25(2), 242–249 (2015).
  MedlineGoogle Scholar